This module uses fundamental data of MoonLake Immunotherapeuti to approximate its Piotroski F score. MoonLake Immunotherapeuti F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of MoonLake Immunotherapeutics. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about MoonLake Immunotherapeuti financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out MoonLake Immunotherapeuti Altman Z Score, MoonLake Immunotherapeuti Correlation, MoonLake Immunotherapeuti Valuation, as well as analyze MoonLake Immunotherapeuti Alpha and Beta and MoonLake Immunotherapeuti Hype Analysis.
MoonLake
Piotroski F Score
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Pb Ratio
Free Cash Flow Per Share
Net Income Per Share
Cash Per Share
Pocfratio
Pfcf Ratio
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Graham Net Net
Enterprise Value Over E B I T D A
Price Earnings Ratio
Price Book Value Ratio
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Return On Capital Employed
Quick Ratio
Cash Ratio
Price To Book Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Return On Assets
Price Fair Value
Return On Equity
Change In Cash
Free Cash Flow
Change In Working Capital
Other Cashflows From Financing Activities
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Net Debt
Retained Earnings
Cash
Non Current Assets Total
Cash And Short Term Investments
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Current Assets
Total Liab
Total Current Assets
Short Term Debt
Common Stock
Depreciation And Amortization
Other Operating Expenses
Operating Income
Ebit
Ebitda
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Probability Of Bankruptcy
At this time, MoonLake Immunotherapeuti's Short and Long Term Debt Total is fairly stable compared to the past year. Interest Debt Per Share is likely to rise to 1.81 in 2024, despite the fact that Net Debt is likely to grow to (425 M). At this time, MoonLake Immunotherapeuti's Ebt Per Ebit is fairly stable compared to the past year. Quick Ratio is likely to rise to 54.17 in 2024, whereas Free Cash Flow Yield is likely to drop (0.02) in 2024.
At this time, it appears that MoonLake Immunotherapeuti's Piotroski F Score is Frail. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
MoonLake Immunotherapeuti Piotroski F Score Drivers
The critical factor to consider when applying the Piotroski F Score to MoonLake Immunotherapeuti is to make sure MoonLake is not a subject of accounting manipulations and runs a healthy internal audit department. So, if MoonLake Immunotherapeuti's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if MoonLake Immunotherapeuti's financial numbers are properly reported.
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between MoonLake Immunotherapeuti's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards MoonLake Immunotherapeuti in a much-optimized way.
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.
Book Value Per Share
10.98
At this time, MoonLake Immunotherapeuti's Book Value Per Share is fairly stable compared to the past year.
MoonLake Immunotherapeuti ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, MoonLake Immunotherapeuti's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to MoonLake Immunotherapeuti's managers, analysts, and investors.
Environmental
Governance
Social
About MoonLake Immunotherapeuti Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze MoonLake Immunotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MoonLake Immunotherapeuti using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MoonLake Immunotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When running MoonLake Immunotherapeuti's price analysis, check to measure MoonLake Immunotherapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MoonLake Immunotherapeuti is operating at the current time. Most of MoonLake Immunotherapeuti's value examination focuses on studying past and present price action to predict the probability of MoonLake Immunotherapeuti's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MoonLake Immunotherapeuti's price. Additionally, you may evaluate how the addition of MoonLake Immunotherapeuti to your portfolios can decrease your overall portfolio volatility.